NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

NCT00314353

TerminatedPhase 2

Sponsor: NSABP Foundation Inc

Conditions: Colorectal Neoplasms

Interventions: Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan

Countries: United States

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Pathological diagnosis of colon or rectal cancer from either the colon or rectum or a metastatic site (beyond the colon or rectum)
* Evidence of adequate organ function (such as liver, kidneys, etc.)

Exclusion Criteria:

* Diagnosis of anal cancer
* Patients who are candidates for surgery
* Patients who have received previous treatments
* Pregnant or lactating women
* History of chronic disease(s) or other serious medical conditions

Locations (1)

Pittsburgh, Pennsylvania, United States